Arsela Prelaj
Arsela Prelaj
Presentazione:
She is a Consultant Medical Oncologist specializing in thoracic malignancies at the Thoracic Unit of Istituto Nazionale Tumori di Milano in Italy since 2018. She completed her residency in Medical Oncology at Sapienza University, Policlinico Umberto I Hospital in Rome, Italy. During her training, she was awarded the ESMO Clinical Unit Visit in 2017 and spent time at The Christie Hospital in Manchester, collaborating with Dr. Raffaele Califano in the Lung Cancer Division from October to December 2017.
Over the past seven years, her research has primarily focused on thoracic malignancies, particularly non-small cell lung cancer (NSCLC) and translational immunotherapy. Since May 2019, she has also directed her research towards the fields of bioengineering and artificial intelligence (AI) and is currently pursuing a Ph.D. at Politecnico di Milano’s Department of Electronics, Informatics, and Bioengineering.
She serves as the principal investigator for multiple international clinical trials and is actively involved in coordinating various national and international grant applications in the field of thoracic malignancies and immunotherapy. As the head of the AI-ON-Lab (Artificial Intelligence for Oncology Lab) at Istituto Nazionale Tumori of Milano, she is responsible for leading research and development in the application of AI in oncology.
Furthermore, she has been appointed as the Responsible for INT's Research Line 4 program, which focuses on big data, clinical research, healthcare, and outcome research. She is an esteemed member of the ESMO Working Group on Real-World Data and Digital Health, and her expertise in AI has led to collaborations with ESMO starting in 2021.
In her capacity as a coordinator, she oversees two significant grants. The first grant, funded by Horizon Europe, is a 10-million project called I3LUNG, dedicated to developing AI and machine learning algorithms to predict immunotherapy efficacy in NSCLC. This collaborative project involves 16 partner institutions. The second project she coordinates is APOLLO 11, a large Italian network focused on translational research, real-world data, and big data platforms for lung cancer patients. The project involves biobanking, federated learning-based data sharing, and analysis utilizing artificial intelligence methodologies.
Additionally, she is engaged in advanced studies concerning the development of a three-dimensional microfluidic device called the Bone Marrow-on-Chip, aiming to detect lung and breast cancer at an early stage. As a principal investigator, she has submitted several European projects and is awaiting the results.
She is an ESMO, ASCO, AACR, IASLC and AIOM member and faculty at many congresses on AI.
Arsela Prelaj
Medico
She is a Consultant Medical Oncologist specializing in thoracic malignancies at the Thoracic Unit of Istituto Nazionale Tumori di Milano in Italy since 2018. She completed her residency in Medical Oncology at Sapienza University, Policlinico Umberto I Hospital in Rome, Italy. During her training, she was awarded the ESMO Clinical Unit Visit in 2017 and spent time at The Christie Hospital in Manchester, collaborating with Dr. Raffaele Califano in the Lung Cancer Division from October to December 2017.
Over the past seven years, her research has primarily focused on thoracic malignancies, particularly non-small cell lung cancer (NSCLC) and translational immunotherapy. Since May 2019, she has also directed her research towards the fields of bioengineering and artificial intelligence (AI) and is currently pursuing a Ph.D. at Politecnico di Milano’s Department of Electronics, Informatics, and Bioengineering.
She serves as the principal investigator for multiple international clinical trials and is actively involved in coordinating various national and international grant applications in the field of thoracic malignancies and immunotherapy. As the head of the AI-ON-Lab (Artificial Intelligence for Oncology Lab) at Istituto Nazionale Tumori of Milano, she is responsible for leading research and development in the application of AI in oncology.
Furthermore, she has been appointed as the Responsible for INT's Research Line 4 program, which focuses on big data, clinical research, healthcare, and outcome research. She is an esteemed member of the ESMO Working Group on Real-World Data and Digital Health, and her expertise in AI has led to collaborations with ESMO starting in 2021.
In her capacity as a coordinator, she oversees two significant grants. The first grant, funded by Horizon Europe, is a 10-million project called I3LUNG, dedicated to developing AI and machine learning algorithms to predict immunotherapy efficacy in NSCLC. This collaborative project involves 16 partner institutions. The second project she coordinates is APOLLO 11, a large Italian network focused on translational research, real-world data, and big data platforms for lung cancer patients. The project involves biobanking, federated learning-based data sharing, and analysis utilizing artificial intelligence methodologies.
Additionally, she is engaged in advanced studies concerning the development of a three-dimensional microfluidic device called the Bone Marrow-on-Chip, aiming to detect lung and breast cancer at an early stage. As a principal investigator, she has submitted several European projects and is awaiting the results.
She is an ESMO, ASCO, AACR, IASLC and AIOM member and faculty at many congresses on AI.